Qiang Shi

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

High Impact

Senior Staff Fellow

NCTR primary UAMS

Also affiliated: Jiangxi University of Traditional Chinese Medicine (2025); Jiangnan University (2011–2013); Jiangsu University (2025); University of Science and Technology of China (2016–2026); Dalhousie University (2018); United States Food and Drug Administration (2008–2026); Zhejiang Sci-Tech University (2023); Center for Drug Evaluation and Research (2020); Shanghai Medical College of Fudan University (2023); North China University of Science and Technology (2022); Nanchang University (2022–2026); Johns Hopkins University (2024); China Three Gorges University (2022); Shanghai Jiao Tong University (2022); Capital Medical University (2007–2017); Liaocheng University (2022); Chinese Academy of Sciences (2022–2026); Shanghai University of Electric Power (2008); Fudan University (2016–2024); Johns Hopkins Medicine (2024); China-Japan Friendship Hospital (2017); Sir Run Run Shaw Hospital (2019); Tianjin Medical University General Hospital (2015); Chinese PLA General Hospital (2023); Soochow University (2022); Shanghai Stomatological Hospital (2023); Chongqing Bureau of Geology and Minerals Exploration (2021–2024); Changchun Institute of Applied Chemistry (2022–2026); Dalian University (2012); Fudan University Shanghai Cancer Center (2023); Ningbo No. 2 Hospital (2022); Hefei National Center for Physical Sciences at Nanoscale (2016); Shanghai Open University (2024); PAREXEL International (United States) (2012); Zhongshan Hospital (2016–2024); First Automotive Works (China) (2023); Changchun University of Chinese Medicine (2023); First Hospital of China Medical University (2009–2011); Shanghai Sixth People's Hospital (2022); Pfizer (China) (2012–2014); State Key Laboratory of Food Science and Technology (2022); State Key Laboratory of Polymer Physics and Chemistry (2022–2026); Center for Life Sciences (2023–2024); Shandong First Medical University (2022–2025); Dezhou University (2010–2013); Hebei University (2005); State Administration for Market Regulation (2026); Xinjiang Agricultural Vocational and Technical University (2022–2024); Jilin Animation Institute (2022); Tianjin Medical University (2015); Northwest Normal University (2023–2024); Zhejiang University (2006–2019); Shaanxi Normal University (2018); China Medical University (2009); Tsinghua University (2023–2024)

36 h-index 197 pubs 10,783 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Qiang Shi's research focuses on drug safety evaluation and the prediction of drug-induced liver injury (DILI). He has contributed to guidelines for assay interpretation in autophagy monitoring and participated in the MicroArray Quality Control (MAQC)-II study, which examined common practices for developing and validating microarray-based predictive models. His work has also involved analyzing FDA-approved drug labeling specifically for the study of DILI and developing systems such as the Drug Induced Liver Injury Prediction System (DILIps) to translate clinical findings into knowledge for drug safety assessment.

Shi has investigated the effects of various compounds on biological systems, including the impact of 31 FDA-approved small-molecule kinase inhibitors on isolated rat liver mitochondria. His research interests also extend to understanding the toxicity of natural products, as indicated by his review of Usnic Acid and Usnea Barbata toxicity. Collaborations within the National Center for Toxicological Research have involved shared publications with researchers such as Laura K. Schnackenberg, Katy S Papineau, and Lijun Ren.

With a career marked by significant scholarly output, Shi has accumulated 209 total publications and 10,795 citations, resulting in an h-index of 36. He is recognized as a highly cited researcher. His work is characterized by investigations into cellular mechanisms, dose-response relationships, and the application of various experimental models, including those involving animals, to assess potential toxicological effects of chemical and drug substances.

Metrics

h-index: 36
Publications: 197
Citations: 10,783

Positions

Senior Staff Fellow 2023–present

US Food and Drug Administration, National Center for Toxicological Research Division of Systems Biology ORCID
Visiting Scientist 2010–2023

National Center for Toxicological Research Systems Biology ORCID

Selected Publications

Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)

Toxicology Letters 4 citations DOI OpenAlex
Toxicity of ubiquitous tire rubber antiozonant N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its transformation product 6PPD-quinone (6PPD-Q) in primary human hepatocytes and liver spheroids (2025)

Biochemistry and Biophysics Reports 4 citations DOI OpenAlex
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)

Biochemical and Biophysical Research Communications 4 citations DOI OpenAlex
Considerations from the pharmaceutical industry (IQ MPS affiliate) workshop on animal microphysiological systems and 3Rs in drug development (2025)

ALTEX 1 citation DOI OpenAlex
New Alternative Methods in Drug Safety Assessment (2023)

DOI OpenAlex